Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 13 2022 - 6:00PM
Esperion (NASDAQ: ESPR) today announced that, on December 9, 2022,
the Compensation Committee of Esperion’s Board of Directors granted
2 new employees 5,600 restricted stock units (RSUs) under
Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used exclusively
for the grant of equity awards to individuals who were not
previously an employee or non-employee director of Esperion (or
following a bona fide period of non-employment), as an inducement
material to such individual's entering into employment with
Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules.
Each RSU will vest and become exercisable as to 25 percent of
the shares on the one-year anniversary of the recipient’s vesting
commencement date and will vest and become exercisable as to the
remaining 75 percent of the shares in twelve equal quarterly
installments at the end of each quarter following such anniversary,
in each case, subject to each such employee's continued employment
with Esperion on such vesting dates. The RSUs are subject to the
terms and conditions of Esperion’s 2017 Inducement Equity Incentive
Plan, and the terms and conditions of the RSU agreement covering
the grant.
Esperion Therapeutics
Esperion works hard to make our medicines easy to get, easy to
take and easy to have. We discover, develop, and commercialize
innovative medicines and combinations to lower cholesterol,
especially for patients whose needs aren’t being met by the status
quo. Our entrepreneurial team of industry leaders is inclusive,
passionate, and resourceful. We are singularly focused on managing
cholesterol so you can improve your health easily. Esperion is the
leader in the development of convenient oral, once-daily non-statin
LDL-cholesterol lowering drugs for patients with high levels of bad
cholesterol. For more information, please visit www.esperion.com
and follow us on Twitter at www.twitter.com/EsperionInc.
Contact:Corporate Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Sep 2023 to Sep 2024